论文部分内容阅读
目的 探讨膀胱癌的多药耐药性 (MDR)以指导灌注化疗用药。 方法 采用免疫组化法检测 4 4例膀胱癌病理标本 ,分析P 糖蛋白 (P gp)、谷胱甘肽S转移酶 (GST π)和拓扑异构酶 (TOPO Ⅱ )的表达情况。 结果 5 4 5 %的病例P gp高表达 ;6 5 9%的病例GST π无表达和低表达 ;TOPO Ⅱ ,高表达 2 9 5 % ,而低表达 6 5 9%。 结论 检测膀胱癌MDR可指导灌注化疗用药。
Objective To investigate the multidrug resistance (MDR) of bladder cancer to guide the infusion chemotherapy. Methods Immunohistochemistry was used to detect the pathological specimens of 44 cases of bladder cancer and the expressions of P gp, GST π and TOPO Ⅱ were analyzed. Results In 54.5% of the cases, the expression of P gp was high. In 65 5% cases, GST π was neither expressed nor overexpressed. TOPO Ⅱ was expressed at a high level of 25.5%, but at a low level of 65.9%. Conclusion Detecting bladder cancer MDR can guide the infusion chemotherapy.